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Intellectual property is associated with the creative work needed to design clinical trials. Two approaches
have developed to protect the intellectual property associated with multicentre trial protocols prior to site
initiation. The ‘open access’ approach involves publishing the protocol, permitting easy access to the
complete protocol. The main advantages of the open access approach are that the protocol is freely available
to all stakeholders, permitting them to discuss the protocol widely with colleagues, assess the quality and
rigour of the protocol, determine the feasibility of conducting the trial at their centre, and after trial
completion, to evaluate the reported findings based on a full understanding of the protocol. The main
potential disadvantage of this approach is the potential for plagiarism; however if that occurred, it should be
easy to identify because of the open access to the original trial protocol, as well as ensure that appropriate
sanctions are used to deal with plagiarism. The ‘restricted access’ approach involves the use of non-disclosure
agreements, legal documents that must be signed between the trial lead centre and collaborative sites.
Potential sites must guarantee they will not disclose any details of the study before they are permitted to
access the protocol. The main advantages of the restricted access approach are for the lead institution and
nominated principal investigator, who protect their intellectual property associated with the trial. The main
disadvantages are that ownership of the protocol and intellectual property is assigned to the lead institution;
defining who ‘needs to know’ about the study protocol is difficult; and the use of non-disclosure agreements
involves review by lawyers and institutional representatives at each site before access is permitted to the
protocol, significantly delaying study implementation and adding substantial indirect costs to research
institutes. This extra step may discourage sites from joining a trial. It is possible that the restricted access
approach may contribute to the failure of well-designed trials without any significant benefit in protecting
intellectual property. Funding agencies should formalize rules around open versus restricted access to the
study protocol just as they have around open access to results.
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Why intellectual property is becoming increasingly
important
Academic institutions and their affiliated investigators are
encountering a rapidly changing research environment, in
which larger numbers of researchers and universities
are competing for increasingly limited government [1], re-
search trust and industry funding. In this competitive
environment, securing research funding for investigator-
initiated clinical trials depends not only on the quality of
grant applications and individual researchers, but also on
the reputation of the academic institutions themselves [2].
The reputation and wealth-generating potential of institu-
tions are influenced by the creative output generated by
faculty members, as well as the ownership and manage-
ment of the intellectual property (IP) associated with that
creative output [2-5].
This paper discusses the intellectual property asso-
ciated with the design of investigator-initiated clinical
trial protocols as a specific example of creative work,
and a trend appearing in which institutions attempt to
prevent expropriation of that intellectual property.Protecting intellectual property
Institutions take a variety of approaches to the manage-
ment and protection of intellectual property. In the case
of investigator-initiated multicentre academic trials, inves-
tigators and their institutions have until recently been
complacent about protecting their intellectual property, at
least partly because it is difficult to identify the intellectual
property associated with such trials. With the advent of
open access journals and easy access to the internet and
trial websites and registries, a commonly used strategy is
to publish the trial protocol. This ‘open access’ approach is
easily recognised by most producers and users of research
evidence, because their main access to research reports is
through publications available in journals and from online
sources.
Another recently noted strategy in Canada is the use of
non-disclosure agreements (NDAs) to protect the details
of study protocols. NDAs are legal documents developed
by the lead academic institution (the ‘sponsor’ of the
research). NDAs must be signed by the site investigator
and an institutional representative of any potential colla-
borating site before they are given access to the research
protocol, a ‘restricted access’ approach. The goal of NDAs
is to limit access to ‘proprietary information’, in this case
the details of the study protocol, to those individuals
(‘employees and agents’) who need to have those details of
the trial before their site decides whether to join the trial.
Should the site investigator or other individual breach the
agreement, ‘remedies at law’ may be pursued by the lead
academic institution.NDAs originated in industry trials. In that instance,
the manufacturer wishes to protect proprietary informa-
tion contained in a protocol, for example details of a
new drug product, that they do not wish to become
widely available. This is not the case with investigator-
initiated trials, which tend to evaluate treatments or
treatment policies that do not require such protection,
and a rigorous protocol is generally composed of ele-
ments that are already validated and published (and as
such, are in the public domain). For example, a rigorous
study design will use valid and reliable methods for
measuring the outcome of treatments or interventions.
Similarly, trial designs will use previously published
methods for subject randomisation, statistical analysis
and other aspects of the study design. The intellectual
property associated with an investigator-initiated trial
protocol is therefore related to the complete package of
trial interventions and procedures.
What this paper is about
This commentary explores the contrasting approaches
to protection of intellectual property (by permitting
open versus restricted access to protocols) taking as
examples two multicentre investigator-initiated trials
currently being conducted in Canada. The two trials are
ongoing international perinatal trials, both funded by the
Canadian Institutes of Health Research and registered
with the International Standard Randomised Controlled
Trial Number Register [6]. Both trials are led by sophis-
ticated trials units incorporating the highest standard of
data management and monitoring, and involve large
networks of committed investigators. Our commentary
is based on documents that are publicly available.
Examples of two trials
CHIPS (control of hypertension in pregnancy study)
CHIPS [7] is led by the University of British Columbia
Maternal Fetal Medicine Division of the Department of
Obstetrics and Gynaecology and the Sunnybrook Re-
search Institute Centre for Mother, Infant and Child
Research (CMICR). The trial will recruit 1,028 pregnant
women in 19 countries. Women with hypertension are
randomised to ‘less tight’ or ‘tight’ control of hyperten-
sion. The primary outcome is a composite of pregnancy
loss plus neonatal intensive care.
In this trial, the investigators safeguarded intellectual
property through open access to the study protocol. The
full protocol was made available online [8] and a brief
summary could be found at The Lancet website [9].
FACT (folic acid clinical trial)
FACT [10], led by the Ottawa Hospital Research Insti-
tute is recruiting 3,656 pregnant women in seven coun-
tries. Pregnant women are randomised to receive either
Table 1 Stakeholder perspectives on open versus restricted access to trial protocols
Stakeholder Open access (online protocol) Restricted access (NDA)*
Advantages Disadvantages Advantages Disadvantages
Lead
investigators
• Authorship acknowledged. • Investigators do not
have control over who
has access to the
protocol.
• Ownership established by the
lead centre.
• Cost and time involved in
establishing and defending
NDAs.
• Plagiarism can be identified.
• Potential for plagiarism
reduced.
• Investigators must adhere to
protocol, or explain reasons why
not.
• Protocol could be
adapted or plagiarized
by other investigators.
• Need to report all
amendments to protocol.
• High degree of rigour associated
with adhering to protocol and
reporting.
• The lead investigator is the
only one given credit for the
protocol; other investigators do
not receive adequate
recognition of the effort that
they have expended in
developing the protocol.
• Co-investigators in other
centres will need to sign NDAs
before being able to establish
the trial in their centre.
• Investigators might be less







• Affiliation acknowledged. • Institution does not
have control over who
has access to the
protocol.
• Ownership by institution
established.




• Public knowledge of funded
study (that is, use of funding).
• Protocol could be
adapted or plagiarized
by other investigators.
• Confidence that protocol will
not be plagiarized.
• Public cannot access study
protocol.
• Less certainty that study will
be conducted as funded.
• Greater accountability of
investigators to adhere to funded
protocol.
• Greater certainty that study will
be conducted as funded.
Industry
funding bodies
• Public knowledge of funded
study (that is, use of funding).
• Widespread access to
protocol.
• Confidence that protocol will
not be plagiarized.
• Less certainty that study will
be conducted as funded.
• Protocol could be
adapted or plagiarized
by other investigators.
• Others (competitors/public) will
not have easy access to funded
study protocol.
• Greater accountability of
investigators to adhere to funded
protocol.
• Greater certainty that study will
be conducted as funded.
Site
collaborators
• Availability of full protocol if they
wish to seek that information.
• May believe that the
protocol is open to
change.
• Availability of full protocol if
they wish to seek that
information, but only if willing to
sign a NDA that has been first
agreed upon by their institution
and the lead investigator’s
institution.
• Cannot share details of the
protocol with colleagues unless
they are involved in the study.• Can share the protocol with
other potential collaborators
within their institution.
• Cost (time/effort) involved in
review and approval of NDA,
even when the site
subsequently decides not to
participate.






• Availability of full protocol if they
wish to seek that information.
• May believe that the
protocol is open to
change.
• Availability of full protocol for
review before joining the study
if NDA is signed.
• Cost involved in legal review
and approval of NDA.
• Co-investigators’ institutions
need to sign NDAs before






• High degree of rigour associated
with adhering to protocol and
reporting.
• Potential for delay in
publication because of
greater rigour required.
• The study is unlikely to be
duplicated.
• Possibility of selective and
biased reporting.
• Possibility of adopting flawed





• Availability of full protocol if they




• Potential trial participants can
be more confident the protocol
is unique.
• Patients would need to ask
specifically for a copy of the
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protocol if they wished to
obtain details of the study.
• Can check that results are
presented as intended.
• Possibility of selective and
biased reporting.




• Potential for replication of
research, leading to availability of
studies for inclusion in meta-
analyses and more rigorous
evidence to support practice.




• Trial is unlikely to be replicated. • Possibility of flawed evidence
being adopted.
• Protocols of publicly funded
research will be openly available
to the public.
*Note that an NDA refers to protection of the protocol before a centre joins a trial, but this table assumes ongoing protection of the protocol during the conduct
of the trial.
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come is development of pre-eclampsia.
When the trial first started, intellectual property was
safeguarded by requiring potential local investigators
and institutions to sign NDAs before the full protocol
was provided for their consideration. Due to the delays
in implementation, frustration of collaborators and ex-
cess use of resources in this process both in the lead trial
center and for other research institutes, this policy was
later abandoned.
Main advantages and disadvantages of each approach
The advantages and disadvantages for each approach are
summarised for each stakeholder in Table 1. The main
stakeholders included are the lead investigators and their
institutions, funding bodies, site collaborators and their
institutions, end users of research, actual and potential
participants, and society more generally. (An NDA refers
to protection of the protocol before a centre joins a trial,
but this analysis assumes ongoing protection of the
protocol during the conduct of the trial, once a sub-site
agreement has been signed).
To summarise, the main advantages of the open access
approach are that the protocol is freely available to all
stakeholders (including potential and active partici-
pants), permitting them to discuss the protocol widely
with colleagues (and family in the case of participants),
assess the quality and rigour of the protocol, determine
the feasibility of conducting the trial at their centre, and
after trial completion, to evaluate the reported findings
based on a full understanding of the protocol. One side
effect of this openness is that both lead investigators and
site collaborators can have a feeling of ownership of the
protocol and the research. A potential societal advantage
would be that replication of the research would lead to
additional evidence being available to guide clinical prac-
tice. The main disadvantage of this approach is the po-
tential for plagiarism; however if that occurred, it shouldbe both reasonably easy to identify because of the open
access to the original trial protocol, as well as ensure
that appropriate sanctions are used to deal with plagiar-
ism (for example those recommended by COPE [11] and
Tri-Agency Framework: Responsible Conduct of Re-
search [12]). A more insidious possibility would be that
a rival group might adopt the protocol with minor
changes, to avoid being accused of plagiarism.
The main advantages of the restricted access approach
are for the lead institution and nominated principal in-
vestigator who protect their intellectual property asso-
ciated with the trial. The main disadvantage is that there
can be only one named institution and investigator, even
if the trial was developed by a multidisciplinary and
multi-institution research team. This approach implies
that the protocol is owned by the lead institution, thus
reducing the collegiality between the lead investigators
and also between the lead investigators and site colla-
borators. Other disadvantages lie in defining who ‘needs
to know’ about the study protocol during the site evalu-
ation of the study, and how much information would
constitute a breach of confidence: it is unclear whether,
for example, presentation of the protocol at departmen-
tal rounds could constitute a breach of NDA. These defi-
nitions should be clear, because NDAs declare the threat
of legal action if the protocol is shared unnecessarily, al-
though it is not evident what legal remedies might be
applied. As well, the use of NDAs involves costs to the
lead site and both potential and actual collaborators, be-
cause the agreement must be reviewed and signed by
each site’s lead investigator, lawyers and institutional
representatives before the site investigator can even
evaluate the merits of the protocol and the feasibility of
study participation at that centre. This extra step, before
the protocol can be discussed locally, will slow the process
of site recruitment, and may even discourage sites from
joining a trial, particularly when the subsequent process of
study approvals is well known to be onerous [13].
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Even if a specific research question is of interest to more
than one research group, the complex and unique features
that make up a multicentre investigator-initiated trial, in-
cluding the study design as well as the infrastructure
needed to run the trial, and the distinctive group or
network of investigators and collaborators, ensure that an
individual trial is unlikely to be replicated exactly, or the
IP expropriated, with or without the protection of NDAs.
Replication of trials is likely to occur only for research
questions that are deemed important by a number of inde-
pendent groups, and the resulting research findings will
benefit society by providing further evidence to inform
best clinical practice.
In academia where research questions usually occur as a
result of clinical controversy, it is often the case that similar
research questions occur spontaneously. This scenario was
well demonstrated during the past decade by trials investi-
gating the use of multiple courses of antenatal steroids in
women at risk of preterm delivery, with outcomes of inter-
est being safety and effectiveness in reducing perinatal
morbidity. That research question was investigated by sev-
eral large research groups, who produced a number of trial
designs that were unique but sufficiently similar to enable
the evidence from the trials to be synthesised to provide
good evidence to inform clinical practice [14]. Further, the
investigators continue to contribute to ongoing debates
about the role and long-term outcomes of antenatal corti-
costeroids. The use of NDAs might decrease the potential
for such international collegiality and limit the value of evi-
dence that is produced from individual trials.
The two peer-reviewed CIHR-funded trials considered
here represent the highest standard of Canadian review
and trial conduct. They illustrate contrasting approaches
to managing intellectual property associated with study
design, which can be broadly described as open access
(CHIPS) and restricted access (FACT) to the protocols.
Both trials are registered with ISRCTN, and therefore
some details of the protocols are openly available from
that register. Unfortunately, despite increasing standard-
isation and widespread use of registries [15-17], many
still regard them as providing insufficient detail about a
particular trial [16,18,19], inadequate reporting of proto-
col amendments [19,20], and lack of quality assurance of
investigator-entered data [16]. As well, trial publications
often show discrepancies from details available in regis-
tries [17,21]. Selective publication of trials and individual
outcomes can lead to bias [18,21-24], with statistically
significant results being favoured [21,22,24]. As a result
of these concerns about trial registries, several commen-
tators have recommended that trial registration should
be supplemented by protocol publication [19,25-27].
Early publication of the protocol would be incompatible
with a restricted access approach.In the past, protocol publication was only possible on
a study website, as represented by CHIPS [8]. Although
peer review and publication is promoted by leading jour-
nals such as The Lancet (where the CHIPS protocol is
published [9]) not all of the protocol details are available.
With the advent of open access journals, prospective
publication of full study protocols in the public domain
is becoming more common (for example in journals
such as Trials [28] and Biomed Central publications
[29]). Publication of protocols in open access journals is
the most accountable way of ensuring that full details of
a study are known. If protocols are made widely avail-
able, authors can be held to the highest standard of
reporting [19,25], including details of changes to primary
outcome or sample size. Even if protocols are published,
final publications may deviate from the initial protocols
[25-27,30], including peer-reviewed government-funded
trials [22], and those published in high-quality journals
[18]. Open access to protocols can help to ensure that
discrepancies between original protocol and eventual
publication are easily identified, even though bias cannot
be entirely eliminated.
One constraint associated with publishing a protocol
is that the investigators must be rigorous in making
amendments to that initial protocol when there are legit-
imate reasons for making changes. Such changes can be
addressed with an addendum to the protocol, and will
be reported in the final publication. The point is that the
details are transparent to journal editors and readers.
NDAs between the lead institution and sub-sites may
represent a legally responsible approach to intellectual
property protection. Unfortunately there are potential
disadvantages: adding an extra legal step into sub-site re-
cruitment will make this process more difficult; NDAs
may reduce academic openness and collegiality between
potential and actual investigators; and restricting the
availability of the protocol could allow investigators to
present selected results. In the case of the FACT Trial,
the use of NDA was short-lived. The additional hurdle
of the NDA was widely criticized by potential colla-
borators, and the principal investigators (including
MW) insisted that the lead institution stop using this
approach.
The use of NDAs is an increasing trend in Canada. If this
trend continues, it will have an impact on the work of clin-
ical trialists, perhaps making even more difficult site re-
cruitment and progress to full site activation. It is well
documented that poor recruitment to trials is the main rea-
son trials fail [31,32], and it is possible that the introduction
of NDAs may contribute to the failure of well-designed
trials without any significant benefit in protecting intellec-
tual property. In institutions where legal departments re-
quire the use of NDAs, investigators should be prepared to
negotiate with their institution to remove this requirement
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Public funding agencies should formalize rules around open
versus restricted access to study protocols of publicly
funded trials, just as they have with regards to open access
to results [33-35].
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